Edward S. Kim, MD, FACP @EdKimMDLCI @levinecancer @AtriumHealth #NSCLC New Data For In Metastatic, Squamous Cell Carcinoma Of The Lung

Edward S. Kim, MD, FACP @EdKimMDLCI @levinecancer @AtriumHealth #NSCLC New Data For In Metastatic, Squamous Cell Carcinoma Of The Lung

User Photo
Cancer-News

1 month
48 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Edward S. Kim, MD, FACP of the Levine Cancer Institute/Carolinas HealthCare System speaks about IASLC NACLC 2020: Boehringer Ingelheim presents new data for Gilotrif® in metastatic, squamous cell carcinoma of the lung, and in EGFR mutation-positive NSCLC.


Ridgefield, Conn., October 13, 2020-Boehringer Ingelheim today announced new Gilotrif ® (afatinib) results, further confirming its activity in lung squamous cell carcinoma and non-small cell lung cancer ( NSCLC) epidermal growth factor receptor mutation-positive (EGFR M+) in a separate review. At the IASLC 2020 North America Conference on Lung Cancer organized by the International Association for the Study of Lung Cancer (NACLC 2020), the results are discussed.

A retrospective, real-world analysis of patients with metastatic squamous NSCLC who have transitioned to first-line pembrolizumab plus platinum-based chemotherapy offers efficacy and safety evidence for afatinib in this second-line setting following immunotherapy (IO). For patients who received second-line afatinib, the median average period to care (TOT) was 7.3 months (95 % confidence interval [CI]; 5.2-8.1). Six patients (pneumonitis, colitis, hepatitis) experienced an occurrence of serious immune-related adverse effects (irAEs). In this second-line setting, this study also assessed chemotherapy, with a median total TOT of 4.2 months (95 percent CI; 3.9-4.9). No irAES was identified in the chemotherapy cohort.

Researchers evaluated the use of afatinib in Asian and non-Asian patients with EGFRm+ NSCLC whose tumors have non-resistant G719X / L861Q / S768I mutations, pooled from randomized clinical trials and real-world studies, in a separate data collection presented at the conference. The analysis showed that afatinib is effective and ethnicity-free in these patients (overall response rate: 66% Asian/59% non-Asian; median response time: 14.7 months/15.9 months; G719X: 62%/65%; L861Q: 60%/50%; S768I: 80%/25%). The analysis showed that afatinib is effective in these patients.

Gilotrif is indicated for first-line treatment in patients with metastatic NSCLC whose tumors, as identified by an FDA-approved examination, have non-resistant EGFR mutations. Gilotrif is also approved for the treatment of patients with advanced lung squamous cell carcinoma whose cancer has progressed after treatment with chemotherapy based on platinum.

IASLC NACLC 2020 Data Presentations Featured:

Real-world efficacy and protection of Afatinib in the treatment of metastatic, squamous cell / mixed histology of lung carcinoma following immunotherapy (IO): a multi-site retrospective map analysis study in the US. October 16, Friday 17:00-18:00 CDT.
EGFR Mutation-positive (EGFRm+) NSCLC Harboring Major Uncommon Mutations Friday, October 16, 17:00-18:00 CDT. Afatinib in Asian and Non-Asian Patients (pts)

Up Next Autoplay
>